| 1 | A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. (Bodeker KL, Smith BJ, Berg DJ, Chandrasekharan C, Sharif S, Fei N, Vollstedt S, Brown H, Chandler M, Lorack A, McMichael S, Wulfekuhle J, Wagner BA, Buettner GR, Allen BG, Caster JM, Dion B, Kamgar M, Buatti JM, Cullen JJ) Redox Biol 2024 Nov;77:103375 |
| 1 | Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. (Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW) Qual Life Res 2024 Oct;33(10):2833-2844 |
| 1 | Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. (Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P) Clin Cancer Res 2024 Feb 01;30(3):522-531 4 Citations |
| 1 | Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. (Simone CB 2nd, Serebrenik AA, Gore EM, Mohindra P, Brown SL, Wang D, Chetty IJ, Vujaskovic Z, Menon S, Thompson J, Fine G, Kaytor MD, Movsas B) Int J Radiat Oncol Biol Phys 2024 Feb 01;118(2):404-414 5 Citations |
| 1 | Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). (Shitara K, George B, Taieb J, Sundar R, Fakih MG, Makris L, Benhadji KA, Ghidini M) J Cancer Res Clin Oncol 2023 Sep;149(11):9361-9374 |
| 1 | Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. (Gupta S, Hanna PE, Ouyang T, Yamada KS, Sawtell R, Wang Q, Katz-Agranov N, Feghali L, Krasner CN, Bouberhan S, Castro CM, Sise ME) J Natl Cancer Inst 2023 Jul 06;115(7):831-837 8 Citations |
| 1 | DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. (Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M) Gynecol Oncol 2023 May;172:82-91 12 Citations |
| 6 | CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3013-3021 4 Citations |
| 1 | Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. (Song Y, Bugada L, Li R, Hu H, Zhang L, Li C, Yuan H, Rajanayake KK, Truchan NA, Wen F, Gao W, Sun D) Sci Transl Med 2022 May 04;14(643):eabl3649 69 Citations |
| 1 | A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. (Lin X, Xu Z, Carey L, Romero J, Makriyannis A, Hillard CJ, Ruggiero E, Dockum M, Houk G, Mackie K, Albrecht PJ, Rice FL, Hohmann AG) Pain 2022 May 01;163(5):834-851 20 Citations |
| 1 | GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. (Thaker PH, Bradley WH, Leath CA 3rd, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD) Clin Cancer Res 2021 Oct 15;27(20):5536-5545 18 Citations |
| 1 | Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. (Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM) Clin Cancer Res 2020 Nov 01;26(21):5668-5681 43 Citations |
| 1 | The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505. (Evans DB) Ann Surg 2020 Sep 01;272(3):487 11 Citations |
| 1 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. (Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K) Clin Cancer Res 2020 Sep 15;26(18):4767-4776 77 Citations |
| 1 | Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. (Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ) Clin Cancer Res 2020 Sep 15;26(18):4814-4822 102 Citations |
| 1 | Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. (Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA) Clin Cancer Res 2020 Mar 15;26(6):1338-1348 40 Citations |
| 1 | Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review. (Chae YK, Saleem N, Roh Y, Bilal H, Viveiros P, Sukhadia B, Lin X, Sheikh MM, Park LC) BMC Cancer 2019 Jul 30;19(1):748 6 Citations |
| 1 | Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. (Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, Ahmad SA, Patel SH, Abbott DE, Schwartz P, Weber SM, Scoggins CR, Martin RCG, Dudeja V, Franceschi D, Livingstone AS, Merchant NB) Ann Surg 2019 Sep;270(3):400-413 131 Citations |
| 1 | Intracellular Trafficking Network and Autophagy of PHBHHx Nanoparticles and their Implications for Drug Delivery. (Sun X, Cheng C, Zhang J, Jin X, Sun S, Mei L, Huang L) Sci Rep 2019 Jul 03;9(1):9585 13 Citations |
| 1 | HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation. (Duan T, Xu Z, Sun F, Wang Y, Zhang J, Luo C, Wang M) Biomed Pharmacother 2019 Sep;117:109121 58 Citations |
| 1 | Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. (Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators) Lancet Oncol 2019 Jun;20(6):862-876 77 Citations |
| 1 | NIR-Light-Activated Combination Therapy with a Precise Ratio of Photosensitizer and Prodrug Using a Host-Guest Strategy. (Chen H, Zeng X, Tham HP, Phua SZF, Cheng W, Zeng W, Shi H, Mei L, Zhao Y) Angew Chem Int Ed Engl 2019 Jun 03;58(23):7641-7646 148 Citations |
| 1 | GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. (Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK) Mol Cancer Ther 2019 May;18(5):969-979 14 Citations |
| 1 | Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. (Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F) Cancer 2019 Feb 01;125(3):463-472 10 Citations |
| 1 | Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. (Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ) JAMA Oncol 2019 Jan 01;5(1):e183773 74 Citations |
| 1 | Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. (Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D) Br J Cancer 2018 May;118(11):1419-1424 6 Citations |
| 1 | Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. (Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC Jr, Sood AK, von Delft F, Ahmed AA) Nat Commun 2018 Feb 02;9(1):476 39 Citations |
| 1 | Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. (Jin Y, Hu W, Liu T, Rana U, Aguilera-Barrantes I, Kong A, Kumar SN, Wang B, Gao P, Wang X, Duan Y, Shi A, Song D, Yang M, Li S, Han B, Zhao G, Fan Z, Miao QR) Cancer Lett 2018 Apr 10;419:233-244 16 Citations |
| 1 | Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. (Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C) Gynecol Oncol 2017 Sep;146(3):477-483 56 Citations |
| 1 | Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. (Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK) J Natl Cancer Inst 2017 Jul 01;109(7) 12 Citations |
| 1 | Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. (Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R) Cancer Chemother Pharmacol 2016 Feb;77(2):357-64 5 Citations |
| 1 | Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. (Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK) Mol Cancer Ther 2015 Dec;14(12):2677-86 9 Citations |
| 1 | Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. (Eng KH, Hanlon BM, Bradley WH, Szender JB) Gynecol Oncol 2015 Nov;139(2):228-35 22 Citations |
| 1 | Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. (Chen Z, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX, Wang Q) Nat Commun 2015 Sep 16;6:8323 77 Citations |
| 1 | Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. (Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R) Ann Oncol 2015 Jul;26(7):1346-52 52 Citations |
| 1 | NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. (Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK) Cancer 2015 Jul 01;121(13):2156-63 43 Citations |
| 1 | SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F) J Natl Cancer Inst 2015 Mar;107(3) 31 Citations |
| 1 | Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. (Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G) Clin Cancer Res 2015 May 01;21(9):2127-37 65 Citations |
| 4 | Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. (Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM, Moran A, Williams CD, Kelley MJ, Whittle J) J Clin Oncol 2015 Feb 20;33(6):567-74 114 Citations |
| 1 | Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics. (Tekade RK, Tekade M, Kumar M, Chauhan AS) Pharm Res 2015 Mar;32(3):910-28 76 Citations |
| 1 | Notch3 pathway alterations in ovarian cancer. (Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK) Cancer Res 2014 Jun 15;74(12):3282-93 59 Citations |
| 2 | Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. (Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J) J Thorac Oncol 2014 May;9(5):702-9 45 Citations |
| 1 | Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. (Cho H, Cho CS, Indig GL, Lavasanifar A, Vakili MR, Kwon GS) PLoS One 2014;9(2):e89968 16 Citations |
| 1 | Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. (Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK) J Natl Cancer Inst 2013 Oct 02;105(19):1485-95 165 Citations |
| 1 | Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. (Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F) Clin Cancer Res 2012 Oct 15;18(20):5816-28 138 Citations |
| 1 | Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. (Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R) Hepatogastroenterology 2012 Jun;59(116):960-4 3 Citations |
| 1 | Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. (Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H) Int J Radiat Oncol Biol Phys 2012 Oct 01;84(2):456-63 90 Citations |
| 1 | Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. (Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J) Mol Cancer Ther 2012 Feb;11(2):308-16 155 Citations |
| 1 | Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. (Jeroudi OM, Abdel-Karim AR, Michael TT, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Raghunathan D, DaSilva M, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES) EuroIntervention 2011 Dec;7(8):948-54 6 Citations |
| 3 | Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. (Kharofa J, Choong N, Wang D, Firat S, Schultz C, Sadasiwan C, Wong S) Int J Radiat Oncol Biol Phys 2012 Jun 01;83(2):690-5 38 Citations |
| 1 | Neuroprotection of paclitaxel against cerebral ischemia/reperfusion-induced brain injury through JNK3 signaling pathway. (Qi SH, Zhao H, Gong JJ, Sun FM, Yue J, Guan QH, Wang M) J Recept Signal Transduct Res 2011 Dec;31(6):402-7 5 Citations |
| 1 | Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons. (Qi X, Hou S, Lepp A, Li R, Basir Z, Lou Z, Chen G) J Biol Chem 2011 Oct 14;286(41):35883-35890 25 Citations |
| 1 | Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial. (Michael TT, Abdel-karim AR, Papayannis A, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES) J Invasive Cardiol 2011 Jun;23(6):216-9 2 Citations |
| 1 | Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. (Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R) Mol Cancer Ther 2011 Jul;10(7):1300-7 20 Citations |
| 1 | Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. (Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S) JACC Cardiovasc Interv 2011 Feb;4(2):176-82 99 Citations |
| 1 | Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. (Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ) Int J Radiat Oncol Biol Phys 2012 Jan 01;82(1):425-34 248 Citations |
| 1 | Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. (Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R) Cancer Chemother Pharmacol 2011 Jul;68(1):247-53 19 Citations |
| 1 | Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. (Lopez JJ, Keyes MJ, Nathan S, Piana R, Pencina M, Dhar G, Marso S, Rao S, Shammo S, Marquardt W, Cohen DJ, Kleiman NS) Am Heart J 2010 Oct;160(4):767-74 11 Citations |
| 1 | Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. (Fuller CK, Charlson JA, Dankle SK, Russell TJ) J Am Acad Dermatol 2010 Oct;63(4):e83-4 36 Citations |
| 1 | A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. (Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H) Int J Radiat Oncol Biol Phys 2010 Jun 01;77(2):367-72 114 Citations |
| 1 | Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. (Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H) J Clin Oncol 2010 May 10;28(14):2475-80 130 Citations |
| 1 | Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. (Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES) JACC Cardiovasc Interv 2009 Sep;2(9):855-60 43 Citations |
| 1 | Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. (Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK) J Clin Oncol 2009 Oct 01;27(28):4727-32 35 Citations |
| 1 | A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. (Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S) J Am Coll Cardiol 2009 Mar 17;53(11):919-28 197 Citations |
| 1 | Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. (Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF) Clin Genitourin Cancer 2009 Jan;7(1):39-42 16 Citations |
| 1 | Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. (Tierney RM, Powell MA, Mutch DG, Gibb RK, Rader JS, Grigsby PW) Radiat Med 2007 Nov;25(9):439-45 15 Citations |
| 1 | Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. (Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G) Clin Cancer Res 2007 Jun 15;13(12):3623-9 14 Citations |
| 1 | Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. (Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G) Cancer 2007 Jun 01;109(11):2190-6 32 Citations |
| 1 | Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer. (Lazarus C, Logemann JA, Pauloski BR, Rademaker AW, Helenowski IB, Vonesh EF, Maccracken E, Mittal BB, Vokes EE, Haraf DJ) Head Neck 2007 Jul;29(7):632-7 91 Citations |
| 1 | Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. (Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R) Mol Cancer Ther 2006 Dec;5(12):2991-3000 33 Citations |
| 1 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? (Wong SJ, Machtay M, Li Y) J Clin Oncol 2006 Jun 10;24(17):2653-8 117 Citations |
| 1 | Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. (Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A) Cancer Invest 2005;23(1):13-8 17 Citations |
| 1 | Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. (Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E) J Clin Oncol 2004 Jul 15;22(14):2856-64 168 Citations |
| 1 | Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. (Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ) Am J Clin Oncol 2004 Feb;27(1):51-6 94 Citations |
| 1 | Apoptotic pathways of epothilone BMS 310705. (Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R, Ganapathi R) Gynecol Oncol 2003 Oct;91(1):173-8 21 Citations |
| 1 | Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. (Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA) Cancer 2003 Aug 01;98(3):610-7 11 Citations |
| 1 | Gemcitabine, Paclitaxel, and piritrexim: a phase I study. (Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP) Am J Clin Oncol 2003 Jun;26(3):280-4 5 Citations |
| 1 | The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. (Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ) Oncogene 2002 Sep 19;21(42):6510-9 158 Citations |
| 1 | Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. (Lenzi R, Yalcin S, Evans DB, Abbruzzese JL) Cancer Invest 2002;20(4):464-72 41 Citations |
| 1 | Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. (Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB) J Clin Oncol 2002 May 15;20(10):2537-44 188 Citations |
| 1 | Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. (Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2001 Mar;8(2):123-32 327 Citations |
| 1 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB) J Clin Oncol 2000 Feb;18(4):860-7 82 Citations |
| 1 | Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. (Miller AR, Pisters PW, Lee JE, Janjan NA, Abbruzzese JL, Evans DB) Hepatogastroenterology 1998;45(21):624-33 9 Citations |
| 1 | Efficacy of taxol in the orpk mouse model of polycystic kidney disease. (Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE) Pediatr Nephrol 1997 Dec;11(6):728-33 26 Citations |
| 1 | Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ) Gynecol Oncol 1997 Sep;66(3):480-6 147 Citations |
| 1 | Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. (Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F) Br J Haematol 1997 Feb;96(2):328-32 37 Citations |
| 1 | Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. (Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG) Cancer 1994 Oct 01;74(7):1891-8 24 Citations |
